BRPI0412459A - composto tendo ação anti-hcv e seu método de produção - Google Patents
composto tendo ação anti-hcv e seu método de produçãoInfo
- Publication number
- BRPI0412459A BRPI0412459A BRPI0412459-6A BRPI0412459A BRPI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A BR PI0412459 A BRPI0412459 A BR PI0412459A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- hcv
- production
- production method
- bond
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
Abstract
"COMPOSTO TENDO AçãO ANTI-HCV E SEU MéTODO DE PRODUçãO". O objetivo da presente invenção é fornecer um composto útil para a prevenção e tratamento de doenças infecciosas virais, e particularmente doenças do fígado causadas pela infecção por HCV, devido a isto tendo um grau elevado de atividade inibidora da replicação contra o HCV, seu método de produção, um composto intermediário útil para a sua produção e uma composição farmacêutica contendo estes compostos, e a presente invenção diz respeito a um composto representado pela fórmula (I) (em que A representa -(CH~ 2~)~ n~-, etc.; B representa -(C=O)-, etc.; D representa (CH~ 2~)~ m~-R<39>, etc.; E representa um átomo de hidrogênio, etc.; G representa (CH~ 2~)~ p~-J, etc.; a ligação Q representa uma ligação única ou ligação dupla; e R~ 1~, R~ 2~ e R~ 3~ podem ser os mesmos ou diferentes e cada um representa um átomo de hidrogênio, etc.), um pró-medicamento deste ou um sal farmaceuticamente aceitável deste.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003272420 | 2003-07-09 | ||
| PCT/JP2004/009803 WO2005005372A1 (ja) | 2003-07-09 | 2004-07-09 | 抗ｈｃｖ作用を有する化合物およびその製法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412459A true BRPI0412459A (pt) | 2006-10-17 |
Family
ID=34055974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412459-6A BRPI0412459A (pt) | 2003-07-09 | 2004-07-09 | composto tendo ação anti-hcv e seu método de produção |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7378446B2 (pt) |
| EP (1) | EP1661882B1 (pt) |
| JP (1) | JP4068639B2 (pt) |
| KR (1) | KR20060029182A (pt) |
| CN (1) | CN1819990B (pt) |
| AU (1) | AU2004255633B2 (pt) |
| BR (1) | BRPI0412459A (pt) |
| CA (1) | CA2531790A1 (pt) |
| HK (1) | HK1093485A1 (pt) |
| IL (1) | IL172666A0 (pt) |
| MX (1) | MXPA06000294A (pt) |
| MY (1) | MY143775A (pt) |
| NO (1) | NO20055986L (pt) |
| NZ (1) | NZ545102A (pt) |
| RU (1) | RU2346933C2 (pt) |
| TW (1) | TWI330173B (pt) |
| UA (1) | UA92134C2 (pt) |
| WO (1) | WO2005005372A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006077004A (ja) * | 2004-08-11 | 2006-03-23 | Chugai Pharmaceut Co Ltd | 抗ｈｃｖ作用を有する化合物およびそれを含む医薬組成物 |
| US8183005B1 (en) | 2004-08-11 | 2012-05-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical agents for treating HCV infections |
| JPWO2006088071A1 (ja) * | 2005-02-17 | 2008-07-03 | 中外製薬株式会社 | 抗ｈｃｖ作用を有する化合物の製造方法およびその中間体 |
| JPWO2007000994A1 (ja) * | 2005-06-28 | 2009-01-22 | 中外製薬株式会社 | 抗ｈｃｖ作用を有する化合物の製造方法 |
| CN101360736A (zh) * | 2005-11-23 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | L-丙氨酸衍生物 |
| CN101489580A (zh) | 2006-05-16 | 2009-07-22 | 财团法人东京都医学研究机构 | 治疗或预防hcv感染症的药物组合物 |
| JP2009539815A (ja) * | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| US20090062267A1 (en) * | 2007-01-29 | 2009-03-05 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS |
| WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| EP2610343A3 (en) | 2008-11-26 | 2013-09-25 | Chugai Seiyaku Kabushiki Kaisha | Method for designing siRNA and oligoribonucleotides inhibiting HCV |
| JP2013121935A (ja) * | 2011-12-12 | 2013-06-20 | Institute Of Microbial Chemistry | 化合物、及び不斉合成反応 |
| EP2886530A4 (en) | 2012-08-17 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | ORAL ADMINISTRATIVE VIRIDIDEIN DERIVATIVE WITH ANTI-HCV ACTIVITY |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364948A (en) * | 1991-08-02 | 1994-11-15 | Merck & Co., Inc. | Biologically active compounds isolated from aerobic fermentation of Trichoderma viride |
| EP0526936A3 (en) * | 1991-08-02 | 1993-05-05 | Merck & Co. Inc. | Cholesterol-lowering agents |
| US5503973A (en) | 1992-05-29 | 1996-04-02 | The Regents Of The University Of California | Method for inhibition of viral morphogenesis |
| US6303350B1 (en) * | 1997-06-09 | 2001-10-16 | Takara Shuzo Co., Ltd. | Physiologically active substances TKR2449, process for producing the same, and microorganism |
| JP5025051B2 (ja) | 2001-07-26 | 2012-09-12 | サトーホールディングス株式会社 | 印字編集処理装置 |
| JP4093534B2 (ja) | 2002-03-15 | 2008-06-04 | スタンレー電気株式会社 | 車両用前照灯 |
| MY141506A (en) | 2003-02-12 | 2010-05-14 | Chugai Pharmaceutical Co Ltd | Virus therapeutic drug |
-
2004
- 2004-07-09 MX MXPA06000294A patent/MXPA06000294A/es active IP Right Grant
- 2004-07-09 NZ NZ545102A patent/NZ545102A/en not_active IP Right Cessation
- 2004-07-09 EP EP04747271.7A patent/EP1661882B1/en not_active Not-in-force
- 2004-07-09 CN CN2004800196454A patent/CN1819990B/zh not_active Expired - Fee Related
- 2004-07-09 RU RU2006103803/04A patent/RU2346933C2/ru not_active IP Right Cessation
- 2004-07-09 KR KR1020067000420A patent/KR20060029182A/ko not_active Application Discontinuation
- 2004-07-09 WO PCT/JP2004/009803 patent/WO2005005372A1/ja active Application Filing
- 2004-07-09 UA UAA200601259A patent/UA92134C2/ru unknown
- 2004-07-09 BR BRPI0412459-6A patent/BRPI0412459A/pt not_active IP Right Cessation
- 2004-07-09 CA CA002531790A patent/CA2531790A1/en not_active Abandoned
- 2004-07-09 TW TW093120575A patent/TWI330173B/zh not_active IP Right Cessation
- 2004-07-09 MY MYPI20042769A patent/MY143775A/en unknown
- 2004-07-09 JP JP2005511532A patent/JP4068639B2/ja not_active Expired - Fee Related
- 2004-07-09 US US10/563,089 patent/US7378446B2/en not_active Expired - Fee Related
- 2004-07-09 AU AU2004255633A patent/AU2004255633B2/en not_active Ceased
-
2005
- 2005-12-16 NO NO20055986A patent/NO20055986L/no not_active Application Discontinuation
- 2005-12-18 IL IL172666A patent/IL172666A0/en unknown
-
2007
- 2007-01-10 HK HK07100371.2A patent/HK1093485A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1661882A1 (en) | 2006-05-31 |
| HK1093485A1 (en) | 2007-03-02 |
| WO2005005372A1 (ja) | 2005-01-20 |
| IL172666A0 (en) | 2006-04-10 |
| TWI330173B (en) | 2010-09-11 |
| CN1819990A (zh) | 2006-08-16 |
| US7378446B2 (en) | 2008-05-27 |
| JP4068639B2 (ja) | 2008-03-26 |
| MXPA06000294A (es) | 2006-04-18 |
| AU2004255633A1 (en) | 2005-01-20 |
| NO20055986L (no) | 2006-02-13 |
| UA92134C2 (ru) | 2010-10-11 |
| CN1819990B (zh) | 2010-04-21 |
| RU2346933C2 (ru) | 2009-02-20 |
| EP1661882B1 (en) | 2013-10-30 |
| US20060194870A1 (en) | 2006-08-31 |
| CA2531790A1 (en) | 2005-01-20 |
| MY143775A (en) | 2011-07-15 |
| EP1661882A4 (en) | 2007-01-31 |
| TW200524847A (en) | 2005-08-01 |
| AU2004255633B2 (en) | 2009-08-06 |
| RU2006103803A (ru) | 2006-08-10 |
| JPWO2005005372A1 (ja) | 2006-08-24 |
| NZ545102A (en) | 2008-11-28 |
| KR20060029182A (ko) | 2006-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412459A (pt) | composto tendo ação anti-hcv e seu método de produção | |
| BR0013667A (pt) | Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos | |
| NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
| WO2006122011A3 (en) | Thiazole compounds and methods of use | |
| BR0310006A (pt) | Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos | |
| BR0313694A (pt) | Derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção | |
| TR201820868T4 (tr) | Sindirilemeyen oligosakkritler içeren besin bileşimi. | |
| RU2002124873A (ru) | Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных | |
| WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| NO20053467L (no) | Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater | |
| BRPI0515628A (pt) | composto de 2-morfolina-4-pirimidona | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| BR0314314A (pt) | Derivados do éter 4-pirrolidina-fenil-benzìlico | |
| WO2005095345A3 (en) | Heteroaryl guanidines as inhibitors of viral replication | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
| HUP0202692A2 (hu) | Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
| BRPI0408295A (pt) | uso de um composto | |
| EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
| BRPI0513806A (pt) | composição medicinal contendo remédio para diabetes | |
| CY1109546T1 (el) | Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας | |
| BRPI0407140A (pt) | Droga terapêutica para vìrus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |